Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Status:
Recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
In this single arm, open label, phase 2 trial, operable patients with stage II-III HR+/HER2+
breast cancer will be enrolled and receive two cycles of pyrotinib combined with trastuzumab,
dalpiciclib and letrozole. Imaging evaluation was performed two weeks later, and patients who
achieved CR or PR were continued with the original regimen for 4 cycles. Subjects who did not
achieve PR switched to regimen and received 4 cycles of pyrotinib combined with trastuzumab
plus chemotherapy. This study aims to assessed the biological effects and safety of pyrotinib
combined with trastuzumab, dalpiciclib and letrozole for HR+/HER2+ breast cancer in the
neoadjuvant setting.